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Xenotropic murine leukemia virus-related virus (XMRV) has been proposed to be associated with prostate
cancer and chronic fatigue syndrome (CFS). This proposition has been controversial because many investi-
gators have failed to replicate the reported associations. Here, we explore whether XMRV is an authentic
human pathogen in the light of recent findings that indicate otherwise.Background
Xenotropic murine leukemia virus-related
virus (XMRV) is a recently described gam-
maretrovirus that was originally detected
in and molecularly cloned from a human
prostate cancer (Urisman et al., 2006). A
later paper reported that XMRV was
present in the blood of 67% of patients
with chronic fatigue syndrome (CFS) and
in 4% of healthy controls (Lombardi
et al., 2009). Since these publications,
some investigators have detected XMRV
in human prostate cancer samples while
others have not (Silverman et al., 2010;
Aloia et al., 2010). Aside from a single
study that reported finding polytropic
murine leukemia virus sequences (a virus
related to but different from XMRV) in
87% of CFS samples (Lo et al., 2010), all
other reports (at least seven) have failed
to detect XMRV in CFS patients from
Europe, China, and the U.S. (van der
Kuyl et al., 2011).
The current state of XMRV as a human
pathogen is controversial and remains
confounding even to themost knowledge-
able retrovirology aficionados. In this
context, it is important to frame two sepa-
rate issues for consideration. First, is
XMRV a physiologically prevalent path-
ogen in humans?Second, basedonwhere
the virus has been detected in humans, isTable 1. Comparative Virus-Cancer Associat
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XMRV Can Infect Human Cells
The receptor for XMRV is XPR1, a cell-
surface protein ubiquitously expressed
inmany human and animal cells. Although
XMRV was originally described as infect-
ing human prostate stromal cells (Urisman
et al., 2006), in vitro assays show that the
virus can infect and replicate in various
human, feral mouse, mink, monkey, and
bovine cell lines (Stieler et al., 2010). A
recent intravenous infection study of eight
adult Indian rhesus macaques (five in-
fected and three mock-infected controls)
used immunohistochemical staining and
in situ hybridization-based assays to
show that the virus was widely dissemi-
nated in vivo. Infected tissues included
lymphoid organs (CD4-positive cells) as
well as the prostatic epithelium and repro-
ductive tract (Onlamoon et al., 2011).
These results show that XMRV has the
capability to infect humans. Nevertheless,
some of the controversy surrounding
XMRV centers on the possibility that
detection of this virus in human samples
is due to contamination from mouse cells
(Smith, 2010). A significant argument
against this stance was the identification
of 14 XMRV integrated proviral se-ions
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(Kim et al., 2008). However, a recent
report showed that 2 of these 14 inte-
grated proviral sequences were contami-
nants from an experimentally infected
cell line that was propagated in the labo-
ratory, raising the question of whether
the other 12 reported XMRV prostate-
cancer integration sequences may not
also be erroneously tainted results (Gar-
son et al., 2011).
Unlike other human pathogenic/onco-
genic viruses such as human T cell
leukemia virus (HTLV-1) or human papil-
loma virus (HPV) (Table 1), there is
currently no conclusively reproducible
epidemiological link for an XMRV-related
human disease (prostate cancer or CFS)
or a natural XMRV reservoir in humans,
mice or other animals (Figure 1). In
contrast to other ‘‘newly discovered’’ viral
infections such as the severe acute respi-
ratory syndrome (SARS) coronavirus or
avian influenza virus, the infection source
of XMRV for humans has remained
elusive. Indeed, some investigators have
argued that the high conservation of
XMRV genome sequences reported from
different geographic locales by multiple
laboratories are inconsistent with signifi-
cant infection or extensive replication of







Figure 1. Unproven Transmission of XMRV from Mice to Humans
The viral reservoir and mode of transmission of XMRV are currently unknown.
The ability of XMRV to replicate in humans in vivo and the link between XMRV
and potential diseases have been questioned by many investigators.
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In developed economies,
prostate cancer is the most
common noncutaneous ma-
lignancy in men. The preva-
lence of prostate cancer is
associated with age. Thus,
approximately 50% of men
over the age of 70 have
asymptomatic in situ prostate
cancer that does not signifi-
cantly impact longevity. Given
the large at-risk population for
prostate cancer, a potential
association with XMRV re-
ported in two studies from
the U.S. (Urisman et al., 2006;
Schlaberg et al., 2009) is
significant, since it suggests
the possible use of antiretrovi-
ral drugs (ARVs) as a thera-
peutic or preventive measure.On the other hand, because ARVs are not
devoid of serious side effects, one must
not use such drugs if XMRV is not the
cause of disease. Therefore, it is vital to
unravel mechanistic explanations re-
garding how XMRV could be oncogenic
in order to carefully consider the plausi-
bility of a virus-prostate cancer link.
Although data from two laboratories
(R. Silverman and I. Singh) were instru-
mental in raising a connection between
XMRV and prostate cancer, there are
critical details on which the two studies
differ (Urisman et al., 2006; Schlaberg
et al., 2009). For example, Silverman and
colleagues (Urisman et al., 2006) reported
that XMRV infection was restricted to
prostatic stromal fibroblasts that surround
malignant prostatic epithelial tissue, while
Singh and coworkers (Schlaberg et al.,
2009) identified XMRV-positive cells
primarily in the cancerous prostatic
epithelium.Anonparsimonious interpreta-
tion of the two studies is that XMRV
causes prostate cancer through more
thanonemechanism. Another conundrum
is that one of the two studies reported an
association between XMRV-cancer and
a function-attenuating R462Q polymor-
phism in the interferon-induced RNASEL
gene in patients (Urisman et al., 2006),
while the other study found no such asso-
ciation (Schlaberg et al., 2009).
A further puzzle is the extremely low
copy number of XMRV genomes present
in putatively virus-positive prostate can-cers. It is well accepted that retroviral
transformation of cells occurs in one of
two ways: transduction by the virus of an
oncogene into the cell (whether a cellular
oncogene or a virus-encoded oncogene
such as HTLV-1 Tax, Table 1) or inser-
tional mutagenesis by the retrovirus that
results in the activation of an endogenous
cellular oncogene. Both mechanisms are
known to result in virus-induced clonal
tumors that contain one or more copies
of the proviral DNA sequence per trans-
formed cell. The finding that XMRV
sequences in virus-positive prostate
cancers exist at fewer than one copy
per cancer cell (Danielson et al., 2010)
posits that either XMRV employs a trans-
formation mechanism unprecedented for
other retroviruses or that virus infection
of the cell per se is not the direct cause
of cancer. In this context, it is relevant (1)
that recent findings have suggested that
XMRV may itself have resulted from
a recombination event involving murine
leukemia virus ancestors (van der Kuyl
et al., 2011) (abstracts from CROI 2011
meeting) that produced a virus that in-
fected human prostate tumor cells being
experimentally passaged in mice, and (2)
that multiple new studies have failed to
detect XMRV sequences in prostate
cancer biopsies.
The Case of XMRV and CFS
The original study that identified a link
between XMRV and CFS (Lombardi et al.,Cell Host & Microbe 9, April 21,2009) remains unconfirmed
andhasbeenquestioned in re-
gard to the prevalence of
in vivo XMRV infection and its
causal disease relationship to
CFS. Like the connection
between XMRV and prostate
cancer, several studies now
claim that the identification of
XMRV sequences in CFS
samples has resulted from
laboratory contamination in-
volving either faulty primers
that were used in PCR
analyses or laboratory tainting
of human-tissue samples by
mouse cells containing XMRV
sequences (Smith, 2010; van
der Kuyl et al., 2011). Others
have failed to identify anti-
bodies to XMRV in the sera of
individuals suffering from CFS
(Satterfield et al., 2011). More-over, there has been no clarification on the
causal mechanism(s) by which XMRV is
responsible for CFS. The fact that XMRV
can infect lymphoid tissues, which is not
contested, does not establish causality of
CFS. This may, in fact, represent a wide
array of discrete conditions of unknown
etiologies thathavebeengrouped together
for reasons of convenience,much asmany
variations of human hepatitis were termed
non-A, non-B for many years, simply
because no other definitive hepatitis
viruses had yet been identified.Unresolved Issues and Future
Perspectives
There is significant uncertainty in postu-
lating a link between XMRV and either
prostate cancer or CFS. Unless and until
more definitive reports of in vivo preva-
lence and disease causality are pub-
lished, it is probably judicious to assume
that some of the currently reported find-
ings may be erroneous. In the bigger
picture of XMRV as a public health
concern, the following risk-benefit
considerations warrant discussion.
1. There is already a suggestion that
blood agencies should immediately
develop screening tools to pre-
vent the potential transfusion of
XMRV in human blood or the
acquisition of XMRV through organ
transplantation. However, there is
still no consensus on the2011 ª2011 Elsevier Inc. 261
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based methodologies that are
most suitable for executing this
screening. In the absence of
conclusive evidence of in vivo prev-
alence and causality (risk) for
diseases, it should be recognized
that the potential development
and implementation of such
screenings would be very expen-
sive and have unquantifiable bene-
fits. Thus, it could be that countless
units of blood would not be
donated or would be sacrificed
needlessly without avail. Decision
makers should be scrupulously
cautious that some individuals
and/or companies might stand to
gain financially from the notion
that XMRV is a human pathogen.
A potential conflict of interest
was recently alleged in reports on
the controversy surrounding the
hypothesis that vaccination with
the measles, mumps, rubella virus
vaccine might cause autism.
Lessons learned from this and other
past episodes could inform cool-
headed deliberations on future
XMRV policies.
2. In regard to CFS, the possibility that
XMRV may be a causal pathogen
has led many affected individuals
to turn to ARVs as possible reme-
dies for their conditions. Usually,
this has involved the use of nucleo-
side reverse transcriptase inhibitors
(NRTIs), since these compounds
have been shown to be active
against the reverse transcriptase
(RT) enzyme of XMRV as well as
against those of HIV-1, HIV-2, and
other retroviruses. At present, there
are no clinical reports of benefit
following such anecdotal use of
ARVs in CFS. Even if XMRV is linked
to some CFS cases, it is almost
certain that many and perhaps
most CFS cases are not caused by
XMRVsinceCFS isaheterogeneous
entity. Scientific and regulatory
communitiesmighthavea responsi-
bility to endorse the appropriate
drug therapy if some cases of
XMRV-CFS could be established
and to strongly discourage the use
of ARVs in cases where it is shownCell Host & Microbe 9, April 21, 2011 ª2011beyond a reasonable doubt that an
XMRV-CFS link does not exist.
3. Decisions regarding therapeutic or
preventive approaches to the
XMRV-prostate cancer question
are equally complex. As stated
above, it has been argued that
approximately 50% of men over
the age of 70 have asymptomatic
in situ prostate cancers that do
not significantly impact longevity.
Because 50% of men over the age
of 70 are unlikely to acquire new
XMRV infection, it is imperative
that one asks how many, if any, of
these age-associated cases are
caused by XMRV. If XMRV does
cause some prostate cancers,
how many longevity-critical cases
versus longevity-neutral cases are
associated with this virus? In the
long run, resource-consuming in-
terventions require a clear cut risk-
benefit justification.
4. An important general issue raised by
the current XMRV-disease debate is
how to approach future medical
questions of this nature. Undoubt-
edly, real and rumor viruses will
continue to be discovered in the
comingyears andprobably at accel-
erated speed with the popularity
of next-generation ultrasensitive
deep-sequencing technology. In
future episodes, what should suffice
asproof of a virus-disease link?How
hard should we chase down every
one, two, or three reports of a path-
ogen-disease axis? Even more
pertinent, how much counterevi-
dence do we need to accumulate
before we stop and close the file on
a virus-disease hypothesis? If the
current XMRV controversy helps to
refine our future decision thinking,
then the considerable energy,
resources, and emotions that have
been expended in this debate could
havebenefitsbeyondCFSandpros-
tate cancer for yet undiscovered
infectious diseases.ACKNOWLEDGMENTS
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